Holen Sie sich die Stockscreener-App
12.34
0.82%
0.10
Schlusskurs vom Vortag:
$12.24
Offen:
$12.62
24-Stunden-Volumen:
565.84K
Relative Volume:
0.86
Marktkapitalisierung:
$772.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.71M
KGV:
-10.34
EPS:
-1.1935
Netto-Cashflow:
$-54.12M
1W Leistung:
+1.82%
1M Leistung:
-20.54%
6M Leistung:
+9.88%
1J Leistung:
+105.15%
1-Tages-Spanne:
$12.24
$12.95
1-Wochen-Bereich:
$11.85
$12.95
52-Wochen-Spanne:
$5.28
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
12.34 | 758.49M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | Jefferies | Buy |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Singapore
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis - The Manila Times
BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design - Business Wire
/C O R R E C T I O N -- Basecamp Research/ - PR Newswire
Basecamp Research raises $140 million to advance AI-designed cell therapies - The Pharma Letter
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com India
Design Therapeutics at Cantor conference: biomarker push takes center stage - Investing.com
DSGN: DT-216 achieved robust biomarker and clinical gains in FA, with pivotal data expected in Q1 2027 - TradingView
Design Therapeutics (DSGN) Slips 0.7% as Shares Trade at Midpoint of Key Support-Resistance RangeArms Index - dars.gov.et
A biotech company's conference chat will be webcast live Sept. 9. - Stock Titan
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Risk Parity Rebalance - vinanet.vn
Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Sahm
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch - Yahoo Finance
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress - Business Wire
Design Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
DSGN Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFiscal Year Earnings - vinanet.vn
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.06% Stock GainMid-Term Outlook - Vinanet
Design Therapeutics Stock Price Forecast. Should You Buy DSGN? - StockInvest.us
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares - Stock Titan
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake - Stock Titan
Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co. - MarketBeat
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - vinanet.vn
Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN - MarketBeat
Design Therapeutics (DSGN) Rises 1.47% as Gene Therapy Plays Draw AttentionMid Cap Momentum - dars.gov.et
Design Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Design Therapeutics Q2 Net Loss Narrows - Moomoo
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Design Therapeutics posts Q2 loss, updates clinical trials - Investing.com
Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - marketbeat.com
Design Therapeutics Q2 net loss narrower than expected - TradingView
Design Therapeutics reports $20.2M Q2 net loss, $207.4M cash as RESTORE-FA advances - TradingView
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary - TradingView
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial - Moomoo
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - marketscreener.com
Design Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Design Therapeutics Inc (DSGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Design Therapeutics (DSGN) to Announce Quarterly Earnings on Thursday - MarketBeat
Design Therapeutics (DSGN) Edges Higher as Stock Tests Key Resistance LevelImpulse Wave - careplusvn.com
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Design Therapeutics Inc (DSGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DSGN|Design Therapeutics Inc|Price:13.990|Chg%:+0.220 - TradingKey
DSGN|Design Therapeutics Inc|Price:13.060|Chg%:+0.300 - TradingKey
Design Therapeutics Inc (DSGN) Institutional Confidence - TradingKey
Design Therapeutics Inc (DSGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Design Therapeutics Inc (DSGN) Balance Sheet - TradingKey
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):